Ubiquitin-independent proteasomal degradation of tumor suppressors by human cytomegalovirus pp71 requires the 19S regulatory particle

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4665-4671

  Winkler, Laura L ^a   Hwang, Jiwon ^b   Kalejta, Robert F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

19S REGULATORY PARTICLE PROTEIN; DAXX PROTEIN; PROTEASOME; PROTEIN PA28 GAMMA; PROTEIN PP71; RETINOBLASTOMA PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RNA INTERFERENCE; UBIQUITINATION; VIRUS ENTRY; VIRUS INHIBITION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE; CYTOMEGALOVIRUS; HUMANS; MICE; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEINS; VIRAL PROTEINS;

HUMAN HERPESVIRUS 5;

EID: 84875802583     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03301-12     Document Type: Article

References (46)

1. Stadtmueller BM, Hill CP. 2011. Proteasome activators. Mol. Cell 41:8-19.
2. Jung T, Catalgol B, Grune T. 2009. The proteasomal system. Mol. Aspects Med. 30:191-296.
3. Krogan NJ, Lam MHY, Fillingham J, Keogh M-C, Gebbia M, Li J, Datta N, Cagney G, Buratowski S, Emili A, Greenblatt JF. 2004. Proteasome involvement in the repair of DNA double-strand breaks. Mol. Cell 16: 1027-1034.
4. Loureiro J, Ploegh HL. 2006. Antigen presentation and the ubiquitinproteasome system in host-pathogen interactions. Adv. Immunol. 92: 225-305.
5. Muratani M, Tansey WP. 2003. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 4:192-201.
6. Nakayama KI, Nakayama K. 2006. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6:369-381.
7. Blanchette P, Branton PE. 2009. Manipulation of the ubiquitinproteasome pathway by small DNA tumor viruses. Virology 384:317-323.
8. Hwang J, Winkler L, Kalejta RF. 2011. Ubiquitin-independent proteasomal degradation during oncogenic viral infections. Biochim. Biophys. Acta 1816:147-157.
9. Kalejta RF, Bechtel JT, Shenk T. 2003. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors. Mol. Cell. Biol. 23:1885-1895.
10. Lee SH, Kalejta RF, Kerry J, Semmes OJ, O'Connor CM, Khan Z, Garcia BA, Shenk T, Murphy E. 2012. BclAF1 restriction factor is neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infection. Proc. Natl. Acad. Sci. U. S. A. 109: 9575-9580.
11. Saffert RT, Kalejta RF. 2006. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J. Virol. 80:3863-3871.
12. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF. 2008. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320:797-799.
13. Hwang J, Kalejta RF. 2007. Proteasome-dependent, ubiquitinindependent degradation of Daxx by the viral pp71 protein in human cytomegalovirus-infected cells. Virology 367:334-338.
14. Kalejta RF, Shenk T. 2003. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl. Acad. Sci. U. S. A. 100:3263-3268.
15. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. 2007. Ubiquitinindependent degradation of cell-cycle inhibitors by the REGγ proteasome. Mol. Cell 26:843-852.
16. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. 2007. Ubiquitin-and ATP-independent proteolytic turnover of p21 by the REGγ-proteasome pathway. Mol. Cell 26:831-842.
17. Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai MJ, O'Malley BW. 2006. The SRC-3/AIB1 coactivator is degraded in a ubiquitin-and ATP-independent manner by the REGgamma proteasome. Cell 124:381-392.
18. Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, Deepe GS, Monaco JJ. 2004. Immune defects in 28-kDa proteasome activator γ-deficient mice. J. Immunol. 172:3948-3954.
19. Cantrell SR, Bresnahan WA. 2006. Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression ofHCMV replication. J. Virol. 80:6188-6191.
20. Khor B, Bredemeyer AL, Huang CY, Turnbull IR, Evans R, Maggi LB, Jr, White JM, Walker LM, Carnes K, Hess RA, Sleckman BP. 2006. Proteasome activator PA200 is required for normal spermatogenesis. Mol. Cell Biol. 26:2999-3007.
21. Bresnahan WA, Shenk TE. 2000. UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells. Proc. Natl. Acad. Sci. U. S. A. 97:14506-14511.
22. Zhu H, Shen Y, Shenk T. 1995. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol. 69:7960-7970.
23. Saffert RT, Kalejta RF. 2007. Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro. J. Virol. 81:9109-9120.
24. Hwang J, Saffert RT, Kalejta RF. 2011. Elongin B-mediated epigenetic alteration of viral chromatin correlates with efficient human cytomegalovirus gene expression and replication. mBio 2(2):e00023-11. doi:10.1128 /mBio.00023-11.
25. Hofmann H, Sindre H, Stamminger T. 2002. Functional interaction between the pp71 protein of human cytomegalovirus and the PMLinteracting protein human Daxx. J. Virol. 76:5769-5783.
26. Fabre B, Lambour T, Delobel J, Amalric F, Monsarrat B, Burlet-Schiltz O, Bousquet-Dubouch M-P. 13 December 2012. Subcellular distribution and dynamics of active proteasome complexes unraveled by a workflow combining in vivo complex cross-linking and quantitative proteomics. Mol. Cell. Proteomics [Epub ahead of print.] doi:10.1074/mcp.M112 .023317 mcp.M112.023317.
27. Rechsteiner M, Hill CP. 2005. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol. 15:27-33.
28. Soza A, Knuehl C, Groettrup M, Henklein P, Tanaka K, Kloetzel P-M. 1997. Expression and subcellular localization of mouse 20S proteasome activator complex PA28. FEBS Lett. 413:27-34.
29. Ustrell V, Hoffman L, Pratt G, Rechsteiner M. 2002. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J. 21:3516-3525.
30. Wu Y, Wang L, Zhou P, Wang G, Zeng Y, Wang Y, Liu J, Zhang B, Liu S, Luo H, Li X. 2011. Regulation of REG[gamma] cellular distribution and function by SUMO modification. Cell Res. 21:807-816.
31. Suzuki R, Moriishi K, Fukuda K, Shirakura M, Ishii K, Shoji I, Wakita T, Miyamura T, Matsuura Y, Suzuki T. 2009. Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism. J. Virol. 83:2389-2392.
32. da Fonseca PC, He J, and Morris EP. 2012. Molecular model of the human 26S proteasome. Mol. Cell 46:54-66.
33. Elsasser S, Chandler-Militello D, Müller B, Hanna J, Finley D. 2004. Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. J. Biol. Chem. 279:26817-26822.
34. Finley D. 2009. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78:477-513.
35. Husnjak K, Elsasser S, Zhang N, Chen X, Randles L, Shi Y, Hofmann K, Walters KJ, Finley D, Dikic I. 2008. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 453:481-488.
36. Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, Aruleba S, Balija V, O'Shaughnessy A, Gnoj L, Scobie K, Chang K, Westbrook T, Cleary M, Sachidanandam R, Richard McCombie W, Elledge SJ, Hannon GJ. 2004. A resource for large-scale RNA-interference-based screens in mammals. Nature 428:427-431.
37. Kaneko T, Hamazaki J, Iemura S, Sasaki K, Furuyama K, Natsume T, Tanaka K, Murata S. 2009. Assembly pathway of the mammalian proteasome base subcomplex is mediated by multiple specific chaperones. Cell 137:914-925.
38. Rubin DM, Glickman MH, Larsen CN, Dhruvakumar S, Finley D. 1998. Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. EMBO J. 17:4909-4919.
39. Verma R, Aravind L, Oania R, McDonald WH, Yates JR, III, Koonin EV, Deshaies RJ. 2002. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298:611-615.
40. Petroski M. 2008. The ubiquitin system, disease, and drug discovery. BMC Biochem. 9:S7. doi:10.1186/1471-2091-9-S1-S7.
41. Jariel-Encontre I, Bossis G, Piechaczyk M. 2008. Ubiquitin-independent degradation of proteins by the proteasome. Biochim. Biophys. Acta 1786: 153-177.
42. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. 2012. Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J. Virol. 86:854-864.
43. Wethkamp N, Hanenberg H, Funke S, Suschek CV, Wetzel W, Heikaus S, Grinstein E, Ramp U, Engers R, Gabbert HE, Mahotka C. 2011. Daxx-β and Daxx-γ, two novel splice variants of the transcriptional corepressor Daxx. J. Biol. Chem. 286:19576-19588.
44. Hwang J, Kalejta RF. 2009. Human cytomegalovirus protein pp71 induces Daxx SUMOylation. J. Virol. 83:6591-6598.
45. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka K, Ichihara A. 1992. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360:597-599.
46. Zhang M, Pickart CM, Coffino P. 2003. Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate. EMBO J. 22:1488-1496